SCHEDULE 13G/A: Woodline Partners LP Discloses 3.9% Passive Stake in Protara Therapeutics

Woodline Partners LP, an investment adviser, has disclosed a 3.9% passive beneficial ownership stake in Protara Therapeutics, Inc., including shares underlying warrants, as of December 31, 2024.

Summary

• Woodline Partners LP, a Delaware limited partnership and investment adviser to Woodline Master Fund LP, filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of 1,331,258 shares of Common Stock in Protara Therapeutics, Inc. (the "Company").
• This ownership represents 3.9% of the Company's outstanding Common Stock.
• The reported ownership includes 478,098 shares of Common Stock issuable upon the exercise of warrants.
• The percentage is calculated based on an aggregate of 34,319,772 shares of Common Stock outstanding, after giving effect to the completion of the Company's public offering as described in its Prospectus Supplement filed on December 11, 2024.
• Woodline Partners LP certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a passive investment by an institutional investor, indicating a neutral to slightly positive sentiment as it shows continued institutional interest in the company. It does not contain any negative operational or financial news from the company itself.

Positives

• An institutional investment adviser, Woodline Partners LP, holds a significant passive stake, indicating a vote of confidence in Protara Therapeutics, Inc.'s long-term prospects.
• The acquisition was stated to be in the ordinary course of business, suggesting a standard investment rather than a speculative or activist position.

Future Outlook

This document, a Schedule 13G filing, does not provide any forward-looking statements or guidance from Protara Therapeutics, Inc. regarding its future operations or financial performance. It solely discloses an investor's passive ownership stake.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Erin Mullen, General Counsel & Chief Compliance Officer of Woodline Partners LP)

Industry Context

This filing indicates continued institutional investor interest in Protara Therapeutics, Inc., which is typically a biotechnology or pharmaceutical company given its name. Passive stakes by investment advisers like Woodline Partners LP are common and generally reflect portfolio diversification or long-term investment strategies within their respective sectors.

Comparison to Industry Standards

• This is a standard passive investment disclosure (Schedule 13G) by an institutional investor, indicating that the stake is below the 5% threshold that would typically trigger a more active disclosure (Schedule 13D).
• The certification that the shares were acquired in the ordinary course of business and not for control purposes aligns with the typical intent behind a Schedule 13G filing by an investment adviser.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, potentially offering some stability or validation of the company's investment appeal.
• Company Management: Awareness of a large passive investor, though no direct impact on operations or strategic direction is implied by this type of filing.

Key Dates

Keywords

Protara Therapeutics, Woodline Partners, Schedule 13G, beneficial ownership, common stock, warrants, investment adviser, passive stake, SEC filing